These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

420 related articles for article (PubMed ID: 24909541)

  • 1. Long-term treatment patterns of testosterone replacement medications.
    Donatucci C; Cui Z; Fang Y; Muram D
    J Sex Med; 2014 Aug; 11(8):2092-9. PubMed ID: 24909541
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Medication adherence and treatment patterns for hypogonadal patients treated with topical testosterone therapy: a retrospective medical claims analysis.
    Schoenfeld MJ; Shortridge E; Cui Z; Muram D
    J Sex Med; 2013 May; 10(5):1401-9. PubMed ID: 23464534
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimal diagnostic measures and thresholds for hypogonadism in men with HIV/AIDS: comparison between 2 transdermal testosterone replacement therapy gels.
    Blick G
    Postgrad Med; 2013 Mar; 125(2):30-9. PubMed ID: 23816769
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of intermission and resumption of long-term testosterone replacement therapy on body weight and metabolic parameters in hypogonadal in middle-aged and elderly men.
    Yassin A; Almehmadi Y; Saad F; Doros G; Gooren L
    Clin Endocrinol (Oxf); 2016 Jan; 84(1):107-14. PubMed ID: 26331709
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The long-term efficacy and safety of a testosterone mucoadhesive buccal tablet in testosterone-deficient men.
    Dinsmore WW; Wyllie MG
    BJU Int; 2012 Jul; 110(2):162-9. PubMed ID: 22288877
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The appropriateness and persistence of testosterone replacement therapy in Ontario.
    Martins D; Yao Z; Tadrous M; Shah BR; Juurlink DN; Mamdani MM; Gomes T;
    Pharmacoepidemiol Drug Saf; 2017 Feb; 26(2):119-126. PubMed ID: 27528454
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factors influencing patient decisions to initiate and discontinue subcutaneous testosterone pellets (Testopel) for treatment of hypogonadism.
    Smith RP; Khanna A; Coward RM; Rajanahally S; Kovac JR; Gonzales MA; Lipshultz LI
    J Sex Med; 2013 Sep; 10(9):2326-33. PubMed ID: 23859250
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prospective assessment of health-related quality of life in men with late-onset hypogonadism who received testosterone replacement therapy.
    Sumii K; Miyake H; Enatsu N; Matsushita K; Fujisawa M
    Andrologia; 2016 Mar; 48(2):198-202. PubMed ID: 25988884
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prostate-specific antigen changes and prostate cancer in hypogonadal men treated with testosterone replacement therapy.
    Coward RM; Simhan J; Carson CC
    BJU Int; 2009 May; 103(9):1179-83. PubMed ID: 19154450
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quality of Life and Sexual Function Benefits of Long-Term Testosterone Treatment: Longitudinal Results From the Registry of Hypogonadism in Men (RHYME).
    Rosen RC; Wu F; Behre HM; Porst H; Meuleman EJH; Maggi M; Romero-Otero J; Martinez-Salamanca JI; Jones TH; Debruyne FMJ; Kurth KH; Hackett GI; Quinton R; Stroberg P; Reisman Y; Pescatori ES; Morales A; Bassas L; Cruz N; Cunningham GR; Wheaton OA;
    J Sex Med; 2017 Sep; 14(9):1104-1115. PubMed ID: 28781213
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Retrospective Analysis of Dose Titration and Serum Testosterone Level Assessments in Patients Treated With Topical Testosterone.
    Muram D; Kaltenboeck A; Boytsov N; Hayes-Larson E; Ivanova J; Birnbaum HG; Swindle R
    Am J Mens Health; 2015 Nov; 9(6):496-505. PubMed ID: 25271142
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of demographic factors and biochemical characteristics on the prostate-specific antigen (PSA) response to testosterone replacement therapy.
    Rhoden EL; Morgentaler A
    Int J Impot Res; 2006; 18(2):201-5. PubMed ID: 16177827
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of changing testosterone gel preparations (Androgel or Testim) among suboptimally responsive hypogonadal men.
    Grober ED; Khera M; Soni SD; Espinoza MG; Lipshultz LI
    Int J Impot Res; 2008; 20(2):213-7. PubMed ID: 17898800
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Testosterone replacement therapy in men with hypogonadism and HIV/AIDS: results from the TRiUS registry.
    Blick G; Khera M; Bhattacharya RK; Kushner H; Miner MM
    Postgrad Med; 2013 Mar; 125(2):19-29. PubMed ID: 23816768
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patient satisfaction with testosterone replacement therapies: the reasons behind the choices.
    Kovac JR; Rajanahally S; Smith RP; Coward RM; Lamb DJ; Lipshultz LI
    J Sex Med; 2014 Feb; 11(2):553-62. PubMed ID: 24344902
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improved sexual function with testosterone replacement therapy in hypogonadal men: real-world data from the Testim Registry in the United States (TRiUS).
    Khera M; Bhattacharya RK; Blick G; Kushner H; Nguyen D; Miner MM
    J Sex Med; 2011 Nov; 8(11):3204-13. PubMed ID: 21834870
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evidence-based medicine update on testosterone replacement therapy (TRT) in male hypogonadism: focus on new formulations.
    Giagulli VA; Triggiani V; Corona G; Carbone D; Licchelli B; Tafaro E; Resta F; Sabbà C; Maggi M; Guastamacchia E
    Curr Pharm Des; 2011; 17(15):1500-11. PubMed ID: 21521164
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Retrospective investigation of testosterone undecanoate depot for the long-term treatment of male hypogonadism in clinical practice.
    Conaglen HM; Paul RG; Yarndley T; Kamp J; Elston MS; Conaglen JV
    J Sex Med; 2014 Feb; 11(2):574-82. PubMed ID: 24279472
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Subjective sexual response to testosterone replacement therapy based on initial serum levels of total testosterone.
    Reyes-Vallejo L; Lazarou S; Morgentaler A
    J Sex Med; 2007 Nov; 4(6):1757-62. PubMed ID: 17087806
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of testosterone replacement therapy withdrawal and re-treatment in hypogonadal elderly men upon obesity, voiding function and prostate safety parameters.
    Yassin A; Nettleship JE; Talib RA; Almehmadi Y; Doros G
    Aging Male; 2016; 19(1):64-9. PubMed ID: 26742589
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.